1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

Margaret von Mehren; Michael C. Heinrich; Suzanne George; John Zalcberg; Sebastian Bauer; Hans Gelderblom; Patrick Schöffski; César Serrano; Robin L. Jones; Steven Attia; Gina Z. D’Amato; Ping Chi; Peter Reichardt; Julie Nicole Meade; V. Reichert; Kelvin Shi; Rodrigo Ruiz‐Soto; Jean Yves Blay

doi:10.1016/j.annonc.2021.08.870

Related publications

Article2020

1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study

John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Nicole Meade, V. Reichert, Kelvin Shi, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay

Article2020

O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS

César Serrano, Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, J. Meade, V. Reichert, Kelvin Shi, Jean Yves Blay, Margaret von Mehren

Article2021

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study

Sebastian Bauer, Michael C. Heinrich, Suzanne George, John Zalcberg, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz‐Soto, Jean Yves Blay, Margaret von Mehren, Patrick Schöffski

Article2022

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Patrick Schöffski, Suzanne George, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz‐Soto, Jean Yves Blay, Margaret von Mehren

Article2021

Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.

John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, Robin L. Jones, Hans Gelderblom, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie Nicole Meade, V. Reichert, Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay